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THE PROBLEM 
1 A  
SUMMARY PAGE 
To investigate any possible increase in effectiveness provided by increased doses of 
some antimotion sickness drugs previously tested on the Pensacola Slow Rotation Room. 
FIND1 NGS 
The most effective preparation i n  this study was hyoscine (1.2 mg) and d-amphetamine 
(20 mg). The total number of tolerated head movements, while on the Slow Rotation Room, 
exceeded the sum of that with these drugs when they were tested alone. The next most 
effective drug was hyoscine (1.2 mg) followed by d-amphetamine (20 mg) and meclizine 
(150 mg) i n  that order. The remaining drugs which included thiethylperazine (Torecan 
30 mg), trimethobenzamide (Tigan 750 mg), and prochlorperazine (Compazine 15 mg) 
were less effective than i n  a previous study when the recommended doses were used. 
.. 
II 
INTRODUCTION 
The antimotion sickness drugs have been studied under a wide variety of  conditions 
(3). The diff iculty of maintaining a standardized test situation under field conditions 
indicates the need for a reliable laboratory method for testing these drugs (9). The 
Slow Rotation Room (SRR), which i s  a laboratory mounted on a human centrifuge at the 
U. S. Naval School of  Aviation Medicine, provided such a standardized test situation 
for an earlier study of  the antimotion sickness drugs (13). Some of the drugs which are 
reported i n  the literature (14) to be effective failed to reduce susceptibility to motion 
sickness in that study. In the present investigation the dose of these drugs was increased 
to investigate the possibility that this might increase their level of effectiveness. 
PROCEDURE 
The subiects for this experiment were ten healthy young Navy enlisted men. Two 
o f  these subjects were rejected due to their having an exceptionally high resistance to 
motion sickness. The remaining subjects were subjected to vestibular caloric studies 
and al l  had normal responses. 
On test days the subjects were given a l ight breakfast of  milk, cereal, and juice. 
The drugs were administered i n  matched oral capsules, one and one-half to two hours 
before the experiment. Double blind and placebo procedures were used throughout the 
study. A rest period of  from 48 to 72 hours was allowed between administration of  each 
drug. Al l  subjects were tested with each of the drugs used. A total of 112 separate 
experiments were performed using six different drugs, one of  which was given in  two 
amounts and was also combined with another. The results were compared with the previ- 
ous study which involved fifteen subjects and utilized the recommended dose of these 
same drugs. 
The drugs and the doses used were as follows: 
Mecl izine 
Hyoscine 
Hyoscine 
d -A mp he ta mi ne 
T hi e thy1 perazi ne 
T r i  methobenzamide 
Prochlorperazine 
PI acebo 
Bona mi ne 
Scopolamine 
Scopol ami ne 
Dexadrine 
Torecon 
Tigan 
Compazine 
Lactose 
150 mg 
0.06 mg 
1.2 mg 
20 mg 
30 mg 
15 mg 
750 mg 
750 mg 
A combination of 1.2 mg hyoscine and 20 mg of  d-amphetamine was also used. 
The subjects were given questionnaires which were f i l led out prior to the test 
procedure to record the side effects produced by the drugs. Medical surveillance was 
maintained for eight hours following administration of the drugs. Blood pressures and 
pulse rates were recorded periodically. 
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To avoid conditioning the subjects against the experiments a scale of  signs and . 
symptoms o f  motion sickness was adopted from previous research (6,lO). This enabled a 
definite diagnosis o f  motion sickness to be made short of  emesis. 
The subjects were required to continually set a sequence of five dials to numbers 
given at four-second intervals by a tape recorder (Figure 1, reference 7). The dials 
were arranged i n  such a manner as to require head movements which approximated the 
stimulation received by the vestibular receptors from the roll, pitch, yaw, and heave of 
a surface vessel or aircraft. The subjects were spun at increasing RPM in the SRR until 
they developed the malaise 1 1 1  (Table I) (6) condition of motion sickness i n  50 head 
movements or less. This was considered to be the subject's basal susceptibility to motion 
sickness. Two control runs and a placebo run were then taken for each subject to con- 
firm this baseline before administration of  the drugs. Placebo runs were given periodi- 
cally throughout and at the end of  the experiment to determine any adaptation of  the 
subjects to the stimulus. I f  a subject completed 300 head movements without developing 
malaise 111,  the test was halted. 
The subjects were isolated i n  the SRR during the test periods except for a television 
monitor and a trained observor who recorded signs and symptoms o f  motion sickness. 
RESULTS 
The therapeutic effect was enhanced by the increased dose with only two of  the 
antimotion sickness preparations used in this project. An increased effectiveness was 
seen with d-amphetamine (20 mg) and with the combination of d-amphetamine (20 mg) 
and hyoscine (1.2 mg). In  a previous study 10 mg of d-amphetamine increased the 
tolerance to motion by 80 per cent or an average increase of  44 head movements over 
the placebo level. In this study the dose of  20 mg of d-amphetamine increased this 
protection to a level of  170 per cent or an average of  92 head movements over the 
placebo level (Figure 2). 
The combination of  hyoscine and d-amphetamine was the most effective preparation 
in both studies. Earlier 0.6 mg of hyoscine with 10 mg o f  d-amphetamine increased the 
tolerated head movements by an average of  133 movements or by 240 per cent. A dose 
of  20 mg d-amphetamine with 1.2 mg hyoscine increased this to an average of  206 move- 
ments or by 375 per cent over the corresponding placebo level. 
Hyoscine (0.6 rng) increased the tolerated head movements by an average of 88 or 
by 160 per cent i n  the f i rs t  study. Doubling the dose of  hyoscine (1.2 mg) i n  the present 
research failed to produce an increase in resistance to motion sickness. This failure to 
increase therapeutic effectiveness with increased dosage was also seen with al l  other 
drugs used in this study with the two exceptions which were mentioned above. A de- 
crease in  effectiveness was seen with increased doses o f  prochlorperazine (Compazine) 
15 mg, trimethobenzamide (Tigan) 750 mg, and meclizine (Bonamine) 150 mg. Thiethyl- 
perazine (Torecan) 30 mg showed the most marked drop i n  effectiveness as the number of 
tolerated head movements fell from an average of 4 less than the placebo to an average 
o f  40 less with the increased dose. 
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Figure 2 
Average Number of Tolerated Head Movements for Each of Drugs Tested. 
Arrows Indicate Effectiveness of Recommended Dose of These Drugs in 
Previous Study, 
5 
The results of the questionnaire on side effects are i n  Table I I  and are reported i n  
percentages to correspond with other side effect studies. The dose of 1.2 mg of hyoscine 
produced marked drowsiness, blurring of vision, fatigue, and nervousness. Hyoscine i n  
the 0.6 mg dose produced a slightly less severe state of  drowsiness, but a greater inci- 
dence of vertigo was reported. The combination of hyoscine (1.2 mg) and d-amphetamine 
(20 mg) caused the largest number of  subjects to report vertigo and stomach awareness. 
The drowsiness reported with this combination was milder than with hyoscine alone. When 
d-amphetamine (20 mg) was administered, some blurring of  vision, vertigo, and nerv- 
ousness were reported. One subject reported a headache which appeared to be due to an 
increase in blood pressure from 125/80 mm Hg to 140/90 mm Hg. This was the greatest 
alteration of blood pressure noted i n  the study and the only report of  headache from this 
dose of d-amphetamine. The mildest drug as indicated by the questionnaire was meclizine 
i n  spite of the dose of 150 mg. One half of the subjects reported no side effects with this 
drug. Trirnethobenzamide (Tigan) had only slightly more side effects reported than did 
mecl izine. Thiethylperazine (Torecan) i n  the 30 mg dose produced considerable drowsi- 
ness and headache but no vertigo was reported. When the lactose placebo was given, 
one third of the subjects reported drowsiness and one sixth reported a headache. 
DISCUSSION 
The Slow Rotation Room appears to offer an excellent test situation for the anti- 
motion sickness drugs. The standardized head movements and rate of  spin permitted the 
same vestibular stimulus to be repeated for each subject through a series of  experiments. 
This controlled test situation permits a more exact comparison o f  the effectiveness of each 
of  a group of antimotion sickness drugs. Such an exact comparison i s  not possible under 
the uncontrolled conditions of  field tests (9). The results of  this study are i n  general 
agreement with the literature (14) i n  that the well-established drugs such as hyoscine 
and mecl izine were most effective. Preparations which were ineffective i n  this research 
were those which have not had extensive testing as antimotion sickness drugs, such as 
thiethylperazine (Torecan) (12), trimethobenzamide (Tigan) (1 3), and prochlorperazine 
(Compazine ) (1). The exception to this was d-amphetamine which has had only a few 
reports of  effectiveness as an antimotion sickness remedy. Prior to World War I I  i t  was 
reported to have antimotion sickness activity by Hi l l  (8). Blackham (2) shortly there- 
after reported it to be one of  the best drugs i n  his study. Since that time i t  has appar- 
ently not been used against motion sickness. In the present research i t  was the second 
most effective drug. In  our previous study i t  also proved to be effective in the 10 mg 
dose. The fact that i t  has proven effective suggests that the sympathomimetics may be a 
promising area for future development of  antimotion sickness drugs. 
The most effective single drug i n  this study was hyoscine (0.6 mg). Doubling this 
dose failed to increase the therapeutic potency; however, i n  combination with d-ampheta- 
mine the increase in tolerance to motion exceeded the sum of the effect of  these drugs 
when used separately. This separation wcu Id have shown an even greater effect except 
for the fact that five of  the eight subjects on this drug completed the full three hundred 
head movements and were halted there. In  two o f  the remaining subjects this drug combi- 
nation produced the best therapeutic effect of the preparations tested. 
6 
. 
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The signs and symptoms of  motion sickness closely resemble the effect of  overactivity 
o f  the parasympathetic nervous system. An overdose of neostigmine which protects acetyl- 
choline, the mediator of  the parasympathetics, produces similar reactions. The effective 
drugs discussed above included a parasympathetic blocking agent and a sympathomimetic; 
this with the aforementioned facts would suggest that part of the mechanism o f  action of 
these drugs could be the result of a shift of  autonomic activity toward the sympathetics. 
-Further support i s  lent  to this contention by the report that dibenzoline, which blocks 
the sympathetics, increases susceptibility to motion sickness (4). 
. , 
The increased dose of meclizine, thiethylperazine, trimethobenzamide, and 
prochlorperazine produced less of  a therapeutic effect than did the recommended dose. 
This decrease in protection has also been observed i n  other studies on the antimotion 
sickness drugs (11). It i s  well established (3) that any factor that irritates the stomach 
lowers the tolerance for motion and this could be a factor with the large doses used here. 
Nausea i s  also a common side effect with overdose of  various drugs. I t  was reported for 
six of the preparations on the side effects questionnaire which was completed by the sub- 
jects before entering the SRR. The decrease i n  potency with increased dose may have 
been related to these facts. 
A review o f  the literature on antimotion sickness drugs indicated that hyoscine and 
meclizine should be of about equal potency. A very significant difference i n  favor of  
hyoscine was found i n  this and in  our earlier study. The British investigators (5) have 
long held that hyoscine i s  the superior drug, while several U. S. reports favor the anti- 
histamines as being the most effective (1 1). A difference i n  strength of  stimulus i n  the 
various studies may be responsible for these divergent reports. Our results strongly support 
the view that hyoscine i s  the drug of choice for prevention of  motion sickness. 
Subjects wi th  defective labyrinths have been studied and have been found to be 
resistant to motion sickness even under the most extreme conditions (6). The side effect 
of  vertigo i n  this study was roughly correlated to potency of  the drugs against motion 
sickness. These observations suggest that these drugs may act at the vestibular receptor 
sites by lowering their sensitivity. I t  i s  difficult, however, to visualize d-amphetamine 
as having this mechanism of action. 
The scale of signs and symptoms used to determine motion sickness gave very good 
results with trained subjects and observers. It would most l ikely be dif f icult  to apply i t  
to untrained personnel under field conditions. The slight but steady rise i n  the basal 
(placebo) tolerance for motion indicated that l i t t le  conditioning against the test occurred. 
This enabled each subject to be tested on a l l  of  the drugs used and also to serve as his own 
control . 
The human centrifuge served as an excellent laboratory device for testing the anti- 
motion sickness drugs. When the semicircular canals had stabilized to the constant rate 
of  spin, no motion was perceived as long as the head remained stationary. With head 
movements the stimulation to the otoliths approximated that received from rough conditions 
i n  a plane or surface vessel. 
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